Dan Leonard

Dan Leonard asked about the drivers of the downside variance in China's performance during the quarter and the performance across different end markets. He also followed up on the pharma reshoring assumption in the 2026 guidance, seeking context and its importance to the forecast.

Answer

President and CEO Padraig McDonnell explained that China was down 4%, below guidance, with most markets down low to mid-single digits, except A&G. He emphasized the business's stability at around $300 million per quarter and confidence in market share. Regarding pharma reshoring, McDonnell noted ongoing conversations with key pharma companies, expecting orders by the end of 2026, with an estimated $1 billion addressable market opportunity for Agilent by 2030.

Dan Leonard questioned the drivers behind the downside variance in China's Q4 performance across different end markets. He also asked about the importance and context of the pharma reshoring assumption included in the 2026 guidance.

Answer

President and CEO Padraig McDonnell stated China was down 4% in Q4, below guidance, with most markets down low to mid-singles except A&G. He noted growth in biopharma and CAM, declines in food and environmental, and expects FY2026 to be flat, maintaining stable market share. Regarding pharma reshoring, Mr. McDonnell indicated active conversations with key pharma companies, anticipating orders by the end of 2026, with an estimated $1 billion addressable market opportunity for Agilent by 2030, representing potential upside to the forecast.

Dan Leonard of UBS sought to reconcile comments about pricing contribution being both 100 basis points and double the prior year's impact. He also asked for more color on the instrument replacement opportunity in the chemical market.

Answer

Interim CFO Rodney Gonsalves clarified that the pricing impact was ~50 bps last year and 100 bps this year, making the comments consistent. Mike Zhang, President of the Applied Markets Group, explained that the chemical market replacement cycle is being driven by a large installed base and customer demand for new technologies, like the 8850 GC, that offer enhanced productivity and sustainability.

Dan Leonard of UBS sought to reconcile the commentary that pricing was a 100 bps tailwind with the statement that its impact doubled year-over-year. He also asked for more context on the scale of the instrument replacement opportunity in the chemical market.

Answer

Interim CFO Rodney Gonsalves clarified the pricing figures, stating the contribution was about 50 bps in the prior year and 100 bps in the current quarter, thus doubling the impact. Mike Zhang, President of the Applied Markets Group, addressed the chemical market replacement cycle, explaining that innovations from platforms like Intuvo are being integrated into current platforms (e.g., the 8850 GC), driving customer adoption for improved productivity and sustainability. He emphasized Agilent's large installed base and strong innovation pipeline as key drivers.

Dan Leonard of UBS asked for color on business trends in China by end market. He also requested a bridge to explain the sequential deceleration in the Q3 organic growth guidance compared to the strong Q2 result.

Answer

CEO Padraig McDonnell described the China market as 'very stable,' with pharma steady and industrials down slightly, and noted growing excitement for a new government stimulus program. CFO Bob McMahon explained the Q3 guidance reflects a more difficult year-over-year comparison and a prudent approach given macro and tariff uncertainties, advising against over-interpreting the sequential change from Q2.

Dan Leonard inquired about the cost implications of the 'Avantor Revival' program, specifically how the increased spending on e-commerce, manufacturing investments, and new hires would balance with margin objectives. He also asked about the risk of further significant share loss following the loss of a couple of large clients, seeking to understand if the company is now in a period of stability or if major opportunities/risks remain.

Answer

Emmanuelle Ligner, President and CEO, stated it's too early to provide precise cost figures for the revival program, emphasizing the need for an accurate, detailed plan that will show impact over several quarters. He confirmed that most very large key account contracts have been renewed, indicating a more stable position with opportunities to gain wallet share, despite past losses still impacting results due to transition time.

Dan Leonard asked about the cost impacts of the Avantor Revival program, including investments in e-commerce, manufacturing, and new hires, and how these balance with margin objectives. He also inquired about the risk of further large share loss, asking if the company is entering a period of stability.

Answer

President and CEO Emmanuel Ligner stated it is too early to quantify the exact cost impacts of the revival program, emphasizing the need for accurate planning before providing numbers, and noted that impacts would unfold over several quarters. He confirmed that most very large key account contracts have been renewed, indicating a more stable position, though past losses continue to have an impact.

Dan Leonard inquired about reconciling Repligen's increased sales guidance with the narrowing of its EBIT margin to the lower end of previous guidance, and sought clarification on the appropriate operating margin expansion for a high-teens revenue growth rate.

Answer

Jason Garland, CFO, expressed satisfaction with Q3 margin performance, noting gross margin fluctuations due to business mix but a 230 basis point expansion year-to-date. He explained that while operating income grew 20% (excluding M&A/currency) against 18% non-organic revenue growth, the full year operating income is projected to be up 25% against 16% non-COVID organic revenue growth. He attributed the margin impact to $2 million in one-time OpEx, FX pressure, and strategic investments for future growth.

Dan Leonard inquired about reconciling the sales guidance increase with the narrowing of EBIT margin to the lower end of the prior guidance, and sought insight into the appropriate level of operating margin expansion for Repligen's high-teens revenue growth rate.

Answer

CFO Jason Garland expressed satisfaction with margin performance, noting that gross margin fluctuates with mix and was up 230 basis points year-to-date. He highlighted that operating income grew approximately 20% year-over-year (excluding M&A and currency impacts) against 18% non-organic revenue growth, demonstrating leverage. For the full year, operating income is projected to increase about 25% (excluding M&A and FX) against 16% non-COVID organic revenue growth. Garland attributed some margin pressure to $2 million in one-time operating expenses related to leadership changes and strategic investments in infrastructure and digital capabilities, emphasizing a balanced view between margin expansion and future growth investments.

Dan Leonard asked about the growth outlook for Revvity's software business embedded in the 2026 framework, considering challenging comps and the impact of a big new product launch.

Answer

Senior Vice President and CFO Max Krakowiak indicated that software organic growth is expected to be in the mid-single digits for 2026, coming off strong high-teens to 20% growth in 2025. He noted that new product introductions (MPIs) take time to ramp up, and emphasized that metrics like ARR, APV, and net retention rate remain strong indicators of the business's health. President and CEO Prahlad Singh added that new MPIs typically take a few quarters to gain traction and contribute significantly. Leonard also inquired about Revvity's M&A strategy in light of its substantial share repurchase activity. Prahlad Singh reiterated a disciplined M&A approach with an active pipeline, but stated that share buybacks currently represent the most attractive return on capital.

Dan Leonard sought clarification on the 'difficult multiyear comps' in immunodiagnostics and questioned the drivers of the foreign currency impact on EBIT margin, noting FX movements didn't seem dramatic.

Answer

CFO Max Krakowiak clarified that on a multiyear stack basis, the underlying growth for immunodiagnostics (ex-China) is consistent for Q3 and Q4. He explained that while the US dollar has weakened significantly since their last update, the primary driver of margin pressure is the volume loss of high-margin assays in China, not FX.

Dan Leonard with UBS followed up on GLP-1s, noting that West's growth appears faster than script data for Novo and Lilly, and asked if this is due to a compounder element or clinical trial participation.

Answer

CEO Eric Green explained that the broader growth drivers for GLP-1s include increased vial usage (stoppers and seals), a pipeline of new molecules in clinical trials, work with several customers, geographical expansion, and support for generics, indicating a broader scope than just script data from the two main customers.

Dan Leonard followed up on GLP-1 growth, questioning if West's growth rate was faster than market script data and if factors like compounder elements or clinical trial participation were contributing.

Answer

CEO Eric Green explained that West's GLP-1 growth is influenced by factors beyond script data, including increased vial usage (stoppers and seals), a robust pipeline of new molecules in clinical trials, engagement with multiple customers, geographical expansion, and support for generics.

Dan Leonard from UBS Group sought to clarify the guidance update, asking if the organic revenue increase was solely due to the Q2 beat and whether there was any pull-forward of demand into the quarter.

Answer

SVP & CFO Bernard Birkett confirmed the Q2 beat was passed through but also noted the full-year HVP components forecast was raised to mid-to-high single-digit growth, reflecting continued second-half optimism. He stated there was no significant pull-forward, attributing the strong results to true underlying demand for NovaChoice and Daikyo CZ products.

Dan Leonard sought clarification on management's 'stay tuned' comment regarding QuantiFERON automation, asking if it implied partnerships beyond the existing one with DiaSorin.

Answer

CEO Thierry Bernard affirmed the strength of the DiaSorin partnership, stating there is no current need for other partners. The alluded-to innovation focuses on enhancing the QuantiFERON test itself to make it simpler, increase throughput, and improve ease of use, in collaboration with DiaSorin. He also mentioned the ongoing development of the QIAreach test for emerging markets.

Dan Leonard of UBS Group questioned whether Bio-Techne's long-term commitment to grow at "market plus 500 basis points" still holds in the current uncertain environment. He also asked how the company plans to achieve 100 basis points of operating margin expansion on low single-digit revenue growth.

Answer

President & CEO Kim Kelderman stated that while outperformance is less predictable in a turbulent market, he has no doubt the company will return to its differentiated growth model of market plus 500+ basis points once clarity returns. CFO James Hippel explained that the fiscal 2026 margin expansion is primarily driven by the divestiture of the Exosome Diagnostics business, which was a ~200 basis point headwind, with some of that benefit being reinvested into core growth pillars.

Dan Leonard of UBS asked about the demand impact of GLP-1 compounding on vials and inquired what proportion of Stevanato's U.S. demand is currently supplied from its U.S. facilities.

Answer

CFO Marco Dal Lago clarified that syringes and cartridges are the predominant formats for GLP-1s, not vials. CEO Franco Stevanato explained that the Fishers plant is still in its early stages, supplying only a small portion of U.S. revenue, with the long-term goal of having the plant serve the U.S. market more fully.

Dan Leonard of UBS inquired about the sources of strength in the Product Inspection business and whether its full-year forecast had been revised. He also asked for the growth rate and outlook for the Process Analytics business.

Answer

CEO Patrick Kaltenbach attributed the strong Product Inspection performance to market share gains driven by a wave of new, innovative products for both mid-range and high-end markets. CFO Shawn Vadala confirmed the full-year outlook for that business was raised to mid-to-high single-digit growth. Regarding Process Analytics, Vadala did not provide a specific growth rate but highlighted strong momentum in bioprocessing and single-use technologies, which was partially offset by softness in the chemical end market.

Dan Leonard from UBS asked for clarification on the impact of China's diagnostic policies (VBP, DRG) on Bio-Rad's specific product mix and inquired about the company's operational strategies for managing the uncertain tariff environment.

Answer

Executive VP & CFO Roop Lakkaraju and President & COO Jonathan DiVincenzo explained that Bio-Rad has not been impacted by VBP and had already factored in DRG policy effects in prior guidance. DiVincenzo noted that Bio-Rad's specialty diagnostics portfolio, particularly quality controls, is less exposed to these reimbursement pressures. Regarding tariffs, DiVincenzo detailed that the company has implemented countermeasures, including diversifying suppliers, shifting manufacturing locations, and building flexibility into its supply chain to mitigate impacts.

Dan Leonard from UBS Group AG followed up on gross margin, asking how the compression from unfavorable business mix should be viewed going forward, especially in relation to the company's long-term margin expansion framework.

Answer

CEO & Chairman Ari Bousbib acknowledged the unfavorable mix from faster-growing real-world evidence and more FSP work will likely continue in the short term. However, he emphasized that the shift to FSP is not a strong long-term trend, noting FSP was a very low single-digit percentage of Q2 net bookings. EVP & CFO Ron Bruehlman added that these dynamics, along with FX impacts, are already factored into the current guidance.

Dan Leonard asked for an elaboration on business trends in China outside of the diagnostics segment and sought to clarify if the full-year EPS guidance would be $0.15 higher based on current foreign exchange rates.

Answer

President & CEO Rainer Blair reported that the China business outside of diagnostics is 'firming up,' with slight growth in bioprocessing and increased activity in life science tools due to stimulus funding. EVP & CFO Matt McGrew clarified that while the math implies the guide could be $0.15-$0.20 higher from favorable FX and respiratory results, the company has not officially flowed that potential upside through to its guidance.

Speaking on behalf of Dan Leonard, an analyst asked for quantification of the transitory headwinds from supply shortages and respiratory revenue conservatism. A second question concerned the timing and completion of the announced $250 million accelerated share repurchase (ASR) program.

Answer

Chief Financial Officer Karleen Oberton quantified the skeletal stop ship impact at roughly $5 million per month and the respiratory conservatism in the range of $10 million to $20 million, but noted the IV fluid impact is still evolving. She also stated that the $250 million ASR is expected to commence in the coming weeks and finish within the fiscal second quarter, providing a prorated benefit in fiscal 2025.